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ORIGINAL ARTICLE
Treatment with anti-C5aR mAb leads to early-onset clinical and
mechanistic effects in the murine delayed-type hypersensitivity
arthritis model
Sara M. Atkinson1,2, Anneline Nansen1, Pernille A. Usher3, Bodil-Cecilie Sondergaard3, Charles R. Mackay4,
Birgitte Friedrichsen5, Chih-Chuan Chang6, Renhong Tang6, Søren Skov2, Claus Haase1, and Lars Hornum1
1Department of Immunopharmacology, Biopharmaceuticals Research Unit, Novo Nordisk A/S, Maaloev, Denmark, 2Department of Veterinary
Disease Biology, Section for Experimental Animal Models, University of Copenhagen, Frederiksberg, Denmark, 3Department of Histology,
Biopharmaceuticals Research Unit, Novo Nordisk A/S, Maaloev, Denmark, 4School of Biomedical Sciences, Monash University, Clayton, Victoria,
Australia, 5Department of Mammalian Cell Technology, Biopharmaceuticals Research Unit, Novo Nordisk A/S, Maaloev, Denmark, and
6Department of Cell Biology, Novo Nordisk A/S, Beijing, China
Abstract
Blockade of the complement cascade at the C5a/C5a receptor (C5aR)-axis is believed to be an
attractive treatment avenue in rheumatoid arthritis (RA). However, the effects of such
interventions during the early phases of arthritis remain to be clarified. In this study we use
the murine delayed-type hypersensitivity arthritis (DTHA) model to study the very early effects of
a blocking, non-depleting anti-C5aR mAb on joint inflammation with treatment synchronised
with disease onset, an approach not previously described. The DTHA model is a single-paw
inflammatory arthritis model characterised by synchronised and rapid disease onset driven by T-
cells, immune complexes and neutrophils. We show that a reduction in paw swelling, bone
erosion, cartilage destruction, synovitis and new bone formation is apparent as little as 60 h after
administration of a single dose of a blocking, non-depleting anti-mouse C5aR mAb. Importantly,
infiltration of neutrophils into the joint and synovium is also reduced following a single dose,
demonstrating that C5aR signalling during the early stage of arthritis regulates neutrophil
infiltration and activation. Furthermore, the number of T-cells in circulation and in the draining
popliteal lymph node is also reduced following a single dose of anti-C5aR, suggesting that
modulation of the C5a/C5aR axis results in effects on the T cell compartment in inflammatory
arthritis. In summary, these data demonstrate that blockade of C5aR leads to rapid and significant
effects on arthritic disease development in a DTHA model strengthening the rationale of C5aR-
blockade as a treatment strategy for RA, especially during the early stages of arthritis flare.
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Introduction
The complement system is part of the innate humoral immune
system, which reacts immediately to defend against patho-
gens. However, complement is also implicated in various
auto-inflammatory diseases, including rheumatoid arthritis
(RA), where it contributes to disease pathology [1]. Immune
complexes in the articular space of RA patients activate the
complement system which results in the production of
complement components of which many are highly active
inflammatory proteins [2]. The complement anaphylatoxin
C5a, which is produced upon complement activation when C5
convertase cleaves C5 into C5a and C5b, is thought to be the
main complement component responsible for tissue damage
in RA [3]. Levels of C5a protein have been found to be
increased in the synovial fluid of RA patients [4], and
expression levels of C5a receptor (C5aR) on macrophages and
fibroblasts in the synovium of RA patients have shown to
correlate with the number of swollen joints [5]. C5aR is
expressed on many cell types, including granulocytes, mono-
cytes, macrophages, dendritic cells, mast cells, osteoblasts
and osteoclasts [6–8]. Expression on T cells, and epithelial
end endothelial cells [9,10], has also been reported.
Dependent on the cell type, ligation of C5a to C5aR leads
to endothelial adhesion, transendothelial migration and
chemotaxis of cells [6,11,12] and results in cell activation,
evident by oxidative burst, granule release and release of
inflammatory mediators such as TNFa, IL-6, IL-1b, vaso-
active amines, matrix metalloproteinases [11,13,14] and
decreased apoptosis of neutrophils [15]. C5a can also
induce osteoclast differentiation from peripheral blood
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mononuclear cells (PBMCs) [8]. All these events are thought
to contribute to the tissue inflammation and destruction seen
in RA. Data from animal models also implicate the C5a-C5aR
axis in arthritis pathology. A vaccine that induces generation
of anti-C5a antibodies has been shown to be effective in
murine collagen-induced arthritis (CIA) in mice [16], and oral
treatment with a small molecule C5a antagonist reduced joint
damage in the rat antigen-induced arthritis model [17]. In
several mouse models of arthritis C5aR-deficient mice show
reduced disease development [18–21]. In human C5aR knock-
in mice, a mouse anti-human C5aR monoclonal antibody
effectively ameliorated neutrophil-dependent K/BN serum
transfer-induced arthritis [22], and it has been shown that anti-
mouse C5aR mAb lowers disease activity when administered
in the early stages of murine CIA [23]. C5aR-blockade could
potentially prevent or abrogate an arthritis flare in patients,
and therefore the purpose of the present study was to study the
early effects of a blocking, non-cell-depleting anti-C5aR
mAb. For this purpose we chose the highly synchronised
delayed-type hypersensitivity arthritis (DTHA) model, previ-
ously described by us [24]. It is a single-paw arthritis model in
C57BL/6 mice, induced by modifying a classical methylated
bovine serum albumin (mBSA)-induced DTH foot pad
response by i.v. administration of an 8–10-fold lower dose
of the anti-type II collagen antibodies (anti-CII) than is
required to induce collagen antibody-induced arthritis (CAIA)
in the C57BL/6 strain. The mice display systemic manifest-
ations and severe paw inflammation and bone erosion, but
only in the antigen-challenged paw. The dose of anti-CII
given to induce DTHA does not have any arthritogenic effect
without combining it with the DTH foot pad response [24].
The model is ideally suited for testing compounds thought to
have an effect in the earliest stages of an arthritis flare
development, as treatment onset can be synchronised pre-
cisely with disease onset, which is defined exactly by the
experimenter as the time of foot pad challenge with mBSA. In
addition, disease incidence is 100% and the variation is low.
In contrast, treatment in the CIA model is often initiated at
first sign of disease, a time when early disease processes have
been ongoing for a while before the appearance of joint
swelling. Additionally, disease incidence in the CIA model is
less than 100% and the variation is relatively large.
In contrast to CAIA and the K/BxN models, disease
development in DTHA is dependent on CD4+ T cells, and
thus adds the dimension of the adaptive immune system while
still being significantly immune-complex and neutrophil-
driven [24]. Depletion of CD4+ T cells prior to immunisation
in DTHA completely prevents disease development [24] and
depletion post induction of arthritis reduces disease severity
significantly (our unpublished data). However, depletion of
CD4+ T cells after initiation of CIA does not ameliorate
disease [25], indicating that T cells are important for CIA
primarily in the immunisation phase after which the B cells
drive disease progression through the production of anti-type
II collagen antibodies. Previously, we have shown that
etanercept (a TNFa-inhibitor) could ameliorate disease in
DTHA both when administered at arthritis induction and post
arthritis induction [24], suggesting predictive validity of the
model for efficacy of new anti-arthritic biologics. Not all
preclinical data generated in the CIA model has been directly
transferrable to RA, including data on anti-IL-1, which
showed good efficacy in CIA, but limited therapeutic
potential in human RA [26]. So, although this anti-C5aR
mAb has previously been tested in the CIA model [23], we
also wished to test its efficacy in the DTHA model, as we
believe that efficacy data with this particular anti-C5aR mAb
from different arthritis models increase the probability of
translatable preclinical data.
In the present study we found that twice weekly treatment
with anti-C5aR mAb initiated at arthritis induction reduced
paw swelling, bone erosion, cartilage destruction, synovitis,
new bone formation and extra-articular inflammation. Our
data also demonstrate that these effects were apparent already
60 h after a single dose of anti-C5aR given at arthritis
induction. This shows that blocking C5aR is efficacious in the
earliest stages of arthritis flare development before the
appearance of joint swelling, which to our knowledge has
not been demonstrated previously in a mouse model. In
previous studies in the CIA model, dosing of the antibody
either took place prior to or after the appearance of joint
inflammation (REF). Due to the variable onset of disease in
the CIA model, treatment at the exact onset of inflammation
is not possible. Our data show reduced infiltration of
neutrophils into the joint space and synovium after a single
dose of anti-C5aR, demonstrating that one of the very early
effects of blocking C5aR is reduced neutrophil chemotaxis
into the inflamed joints. Levels of several neutrophil-
associated proinflammatory mediators in the affected paw
were also decreased indicating decrease in neutrophil activa-
tion. In addition, numbers of T cells in circulation and the
draining popliteal lymph node were reduced following a
single dose of anti-C5aR, which has not been shown
previously in a mouse model of arthritis, and indicates
interplay between the complement system and the T-cell
compartment in arthritis. In summary, these data demonstrate
that blockade of C5aR-signalling in DTHA leads to rapid-
onset effects reducing leukocyte activation and joint infiltra-
tion of neutrophils, bone erosion, synovitis and cartilage
destruction. Thus, these results strengthen the potential of
C5aR-blockade as a treatment strategy for RA and demon-
strate that C5aR signalling plays a role in the earliest stages of
arthritis flare.
Materials and methods
Mice
Female C57BL/6J mice (Taconic, Denmark) of 8–10 weeks of
age were used. Animals were housed in a facility with a 12 h
light/dark cycle and with free access to water and standard
rodent chow (Altromin). All animal experiments were
conducted according to Danish legislation and have been
approved by the Danish Animal Inspectorate and the Novo
Nordisk ethical review board.
Induction and assessment of DTH-arthritis
Mice were anaesthetised by isoflurane/O2/N2O and immu-
nised intradermally (i.d.) with methylated bovine serum
albumin (mBSA) (Sigma, St. Louis, MO) emulsified in
complete Freund’s adjuvant (CFA) (Difco, Detroit, MI) at the
DOI: 10.3109/08916934.2015.1031888 Early-onset effects of C5aR-blockade in murine arthritis 461
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base of the tail. Four days later they received 1000mg (approx.
50 mg/kg) anti-mouse type II collagen antibody (anti-CII)
cocktail (Chondrex, Redmond, WA) containing the clones
A2-10 (IgG2a), F10-21 (IgG2a), D8-6 (IgG2a), D1-2G
(IgG2b), and D2-112 (IgG2b) intravenously (i.v.) in 200 ml
phosphate-buffered saline (PBS). Isotype control cocktail was
mixed using mIgG2a and mIgG2b (BioXcell, West Lebanon,
NH) in the same ratio as the anti-CII cocktail. Seven days
after immunisation the mice were challenged with 200 mg
mBSA subcutaneously in 20 ml PBS in the right foot pad. The
left foot pad was given 20 ml PBS only and served as control.
Baseline paw and ankle measurements were made on the right
paw on day 0 prior to mBSA challenge. Paw and ankle
swelling was measured using a dial thickness gauge
(Mitutoyo, Japan), and was calculated as right paw or ankle
thickness minus baseline measurement.
Test compounds and dosing of mice
Mice received either two weekly doses intraperitoneally (i.p.)
over two weeks or one single dose (i.p.) of the following
compounds: mouse anti-C5aR IgG2a.1, 0.5 mg/mouse cor-
responding to 25 mg/kg, or anti-TNP mouse IgG2a.1, 0.5 mg/
mouse corresponding to 25 mg/kg, endotoxin levels50.1 EU/
mg. Mice were sacrificed after two weeks of treatment or 60 h
(2.5 days) after a single dose.
Design of mIgG2a.1 antibody
The variable region for the heavy-chain (HC) and light-chain
(LC) was derived from the rat anti-mouse anti-C5aR mAb
20/70, a kind gift from Prof. Dr. Jo¨rg Zwirner [27]. The
constant region of LC is mouse kappa and the constant region
of HC is mouse IgG2a designed with six mutations in the FC
region, resulting in mIgG2a.1. The engineered mutations
L234A, L235E, G237A (ADCC inactivation), D327Q, A330S
and P331S (CDC inactivation) were made to reduce ADCC
or CDC effector mechanisms. Lack of binding to mouse
Fc-gamma receptors I–IV was determined by surface plasmon
resonance analysis. The resulting anti-C5aR mIgG2a.1 mAb
was non-depleting (Supplemental Figure S1). The anti-
trinitrophenol (TNP) control mIgG2a.1 contained the same
six mutations as the anti-C5aR antibody.
Histopathology
Paws were processed and stained with hematoxylin and eosin
(H&E), Safranin O and for tartrate resistant acid phosphatase
(TRAP) as previously described [24]. TRAP stains osteoclasts
red, and Safranin O stains cartilage red. The intensity of red in
the Safranin O stain is inversely proportional to the degree of
proteoglycan depletion from cartilage. Pathological changes
in the paws were assessed on HE, TRAP and Safranin O
stained sections. The extra-articular infiltration of inflamma-
tory cells (assessed on a scale of 0–3) and arthritic changes
were assessed separately. Arthritic changes were assessed on
metatarsal and tarsal joints, respectively, where synovitis,
cartilage destruction and bone erosion were scored separately
on a 0–3 scale. For each of the three parameters of
arthritic changes, an average between the two joint
areas was calculated. In addition, new bone formation and
extra-articular infiltration overall in the paw was scored on a
0-3 scale. The histology sum score was calculated by adding
the five scores (extra-articular infiltration, synovitis, cartilage
destruction, bone erosion and bone formation), whereas the
extra-articular infiltration score is left out in the arthritis
score. The person who performed the evaluation was blinded
to the experimental setup.
Immunohistochemistry and digitalised image analysis
For immunohistochemical (IHC) detection of macrophages
and neutrophils in the paws, paraffin sections were pre-treated
with 10 mg/ml proteinase K for 10 min at 37 C, and incubated
overnight at 4 C with primary antibodies. Macrophages were
detected with 4 mg/ml rat anti-mouse F4/80 (IgG2b, Abcam,
Cambridge, UK) and neutrophils with 2 mg/ml anti-mouse
anti-Ly6B.2 (IgG2b, Ab Serotec, Nordic Biosite,
Copenhagen, Denmark). Rat IgG2b and IgG2a isotype
controls were applied on adjacent sections at the same
concentrations. The primary antibodies were detected with
rabbit–anti-rat antibodies (Dako, Glostrup, Denmark) fol-
lowed by incubation with HRP labeled EnVision + System
(Dako, Glostrup, Denmark). To visualise the target expres-
sion, sections were incubated with DAB (3-30-diamino-
benzidine-tetrahydrochloride) (Sigma-Aldrich) for 5 min and
counterstained with hematoxylin. The sections were all
digitally scanned and studied by using a NanoZoomer
Digital Pathology Virtual Slide Viewer (Hamamatsu
Photonic, Shizuoka, Japan). Automated digital image analyses
of the infiltrating macrophages (F4/80) and neutrophils
(Ly6B.2) in the paws were performed using the Visiopharm
Integrator System (VIS, version 4.2.2.0, Visiopharm,
Hoersholm, Denmark). On individual digital images of the
arthritic paw, a region-of-interest (ROI) was automatically
defined of the entire paw, and the bone marrow was outlined
manually. Next, an analysis was run inside the ROI to detect
the brown DAB staining of the specific IHC immunostaining,
followed by a calculation step. The results are given as tissue
area stained with F4/80 and Ly6B.2 of the entire paw area
(%). Semi-quantitative visual scoring of neutrophil and
macrophage influx into the synovium and joint space was
performed on the Ly6B.2 and F4/80 stained sections,
respectively, on a scale of 0-3, indicating the degree of
neutrophil or macrophage influx into the synovium and joint
spaces. The tarsal and metatarsal joints were scored as
two separate areas, and the final score calculated as the
average between the two. The evaluation of infiltration was
performed by two individual people who were blinded to the
experimental setup. Only the synovium tissue and joint space
area was included in the semi-quantitative analysis, in contrast
to the digitalised image analysis which analysed the entire
paw section, leaving out the contribution from the bone
marrow.
Enzyme-linked immunosorbent assays (ELISAs)
Levels of serum amyloid P component (SAP) were measured
in serum from mice with DTH-arthritis using sandwich
ELISA kits (Genway, San Diego, CA) according to the
manufacturer’s instructions. Levels of MPO in whole-paw
homogenates were measured using sandwich ELISA kits
462 S. M. Atkinson et al. Autoimmunity, 2015; 48(7): 460–470
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(Hycult Biotech, Uden, The Netherlands) according to the
manufacturer’s instructions. Paw homogenates for analysis of
MPO were prepared in a custom-made buffer containing was
a solution of 200 mM NaCl, 5 mM EDTA, 10 mM Tris, 10%
glycerin, 1 mM PMSF, 1 mg/ml leupeptin and 28 mg/ml
aprotinin with a pH value of 7.4 (Ampliqon, Skovlunde,
Denmark). Levels of C5a in whole-paw homogenate super-
natants were analysed by sandwich ELISA using the follow-
ing reagents (all from BD Biosciences, Franklin Lakes, NJ):
Capture rat anti-mouse C5a mAb, standard recombinant
mouse C5a, detection biotin-conjugated rat anti-mouse C5a
mAb, avidin-horseradish peroxidase (HRP) and reagent set B.
The serine protease inhibitor FUT-175 (Calbiochem,
Billerica, MA) was added to the homogenising buffer in
order to preserve C5a protein. Levels of receptor-activator of
nuclear factor kappa B (RANKL) were measured in serum
from mice with DTH-arthritis using sandwich ELISA kits
(R&D Systems, Minneapolis, MN) according to the manu-
facturer’s instructions.
Multiplex analysis of inflammatory markers in paw
homogenate
Paw homogenate supernatants from arthritic hind paws were
prepared as previously described [24]. The supernatants
were analysed undiluted for levels of inflammatory markers
using bead-based Luminex xMAP technology with
Milliplex kits from Millipore (Billerica, MA) according to
the manufacturer’s instructions. For statistical analysis, any
values below the detection limit were set to the detection
limit for the analyte in question and any values above
detection limit was set to the upper detection limit for the
analyte in question. In the case of vascular cell adhesion
molecule 1 (VCAM-1), basic fibroblast growth factor
(bFGF) and lymphotactin the analysis was performed using
a 58-biomarker multi-analyte profile (RodentMAP, Myriad
RBM, Austin, USA).
Flow cytometry
Single-cell suspensions of whole-paws and lymph nodes were
prepared as previously described [24]. All samples were
subjected to Fc-blocking prior to antibody staining using anti-
CD16/32 (BD Bioscience). Dead cells in paw and lymph node
preparations were excluded using Fixable Near IR Vital dye
(Invitrogen, Carlsbad, CA). When analysing blood samples,
red blood cells were lysed with FACS lysing solution (BD
Bioscience) after antibody staining. The following antibody-
fluorochrome conjugations were used for flow cytometry:
Anti-CD88-PE, clone 20/70 (Biolegend, San Diego, CA),
anti-CD45-PerCP, clone 30-F11 (BD Biosciences), anti-CD4-
Qdot605, clone RM4-5 (Invitrogen, Carlsbad, CA), anti-
TCRb-Qdot 655, clone H57-597 (Invitrogen, Carlsbad, CA),
anti-CD45-efluor450, clone 30-F11 (eBioscience, San Diego,
CA), anti-TCRb-PE-Cy7, clone H57-597 (Biolegend, San
Diego, CA), anti-CD19-PerCP-Cy5.5, clone 1D3 (BD
Biosciences), anti-Ly6G-PE, clone 1A8 (BD Biosciences),
anti-CD11b-AF700, clone M1/70 (eBioscience, San Diego,
CA), anti-CD88-FITC, clone 20/70 (Cedarlane, Ontario,
Canada). For determination of blood cell counts, TruCount
beads (BD Biosciences) were added to the samples prior to
acquisition and the cell counts determined from the ratio of
collected beads to total beads.
Statistics
Statistical analyses were conducted using GraphPad Prism
software version 5.01 (La Jolla, CA). Non-parametric data
or non-normal parametric data were analysed using the
Mann–Whitney U-test, and parametric data were analysed
using a two-sided unpaired Student’s t-test. For statistical
analysis of the histology score data a two-sided unpaired
Student’s t-test with Welch’s correction was used. Differences
between groups were considered significant when p 0.05
and levels of significance were assigned as *: p 0.05, **:
p 0.01 and ***: p 0.001.
Results
C5aR is expressed in inflamed paw tissue and on
major leukocyte populations
For induction of DTHA, mice were immunised with mBSA in
CFA and 4 days later given an anti-CII cocktail i.v. Mice were
challenged with mBSA in the right hind foot pad 7 days after
immunisation (Figure 1A). The left hind foot pad received
PBS and served as an intra-animal control. In this first part of
experiment an isotype control group was included to illustrate
the effect of the anti-CII cocktail on paw and ankle swelling in
combination with the DTH response. The anti-CII cocktail
does not induce any paw and ankle swelling without the
mBSA challenge [24]. To confirm the production of C5a in
DTHA and the presence of C5aR on immune cell subsets, the
expression levels in arthritic paws and major leukocyte
subsets during disease were evaluated. Up-regulation of C5a
was observed in the arthritic paw in the initial stages of the
disease, by assaying whole-paw homogenates by ELISA
(Figure 1C). Flow cytometry analysis showed C5aR+ neutro-
phils and macrophages in the affected paw. C5aR-expression
on paw-infiltrating neutrophils was lower than the expression
seen on neutrophils in the blood (Figure 1D and E) and this
down-regulation could be an effect of agonist-mediated
receptor internalisation, which is known to occur [28]. In
the macrophage/monocyte compartment two distinct popula-
tions were seen; a C5aR+ and a C5aR, while the neutrophil
compartment consisted of one population with varying C5aR
expression levels (Figure 1D and E). Marked neutrophilia in
DTHA was observed, which peaked 12–24 h post arthritis
induction, both in blood as measured by flow cytometry
(Figure 1F), and in arthritic paws as measured indirectly as
MPO in whole-paw homogenates (Figure 1G), where the peak
occurred at 60 h post arthritis induction. Taken together, these
data demonstrate that in the DTHA paw C5a levels are up-
regulated, C5aR+ neutrophils and macrophages are present,
and C5a ligation may have taken place with potential effects
on activation and migratory activity in these cells.
Treatment with anti-C5aR mAb ameliorates DTH
arthritis
With confirmed activation of the target pathway, an efficacy
study was performed. Mice with DTHA were dosed twice
weekly with 500 mg anti-C5aR mAb or isotype-matched anti-
DOI: 10.3109/08916934.2015.1031888 Early-onset effects of C5aR-blockade in murine arthritis 463
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TNP mAb (IgG2a.1) from the time of arthritis induction
(Figure 2A). Treatment with anti-C5aR mAb significantly
reduced both paw and ankle swelling in DTHA compared to
the IgG2a.1 control group (Figure 2B). Histopathological
evaluation at study end revealed a significant reduction in
synovitis, cartilage destruction, bone erosion, new bone
formation and extra-articular inflammation (Figure 2C
and E) and in the overall histopathology score in the anti-
C5aR-treated mice (Figure 2D). C5a levels in paw tissue were
increased in the C5aR-treated groups 24 h post arthritis
induction, probably reflecting the blockade of C5aR, as this
would inhibit the clearance of C5a by internalisation via the
receptor [28] (Figure 2F). On day 2.5 (60 h) post arthritis
induction, levels of C5a were not significantly increased. This
could reflect a lower production of C5a in the anti-C5aR
group due to a generally lowered level of inflammation at this
time (Figure 2F). Serum level of the murine acute-phase
protein serum amyloid P component (SAP) was measured at
2.5 (60 h), 5 and 11 days post-arthritis induction to examine
whether anti-C5aR-treatment had an effect on systemic
inflammation. Anti-C5aR-treatment led to reduced SAP
levels in serum on days 2.5 (60 h) and 5 post arthritis
induction (Figure 2G). Taken together, these data demonstrate
that treatment with anti-C5aR led to a significant reduction in
disease activity in DTHA, both locally and systemically.
Single dose treatment with anti-C5aR results in
reduced disease activity after 60 h
Having shown that treatment with anti-C5aR mAb could
attenuate DTHA disease activity in a multiple dose study, we
Figure 1. C5aR is a therapeutic target in DTHA. (A) DTHA was induced by modification of a classical mBSA-induced DTH response. Mice were
immunised with mBSA in CFA on day -7, and the modification consisted of giving the mice a sub-arthritogenic dose of an anti-type II collagen mAb
cocktail (anti-CII) or isotype control cocktail i.v. on day-3. Challenge with mBSA in the right hind foot pad was done on day 0. (B) Temporal course of
the DTH response. The group given isotype control Ab cocktail developed only an acute DTH response. Paw and ankle swelling was calculated as
the swelling on a given day, minus the swelling on day 0. Mean ± 95% CI shown, n¼ 24 (anti-CII group) and n¼ 6 (isotype control group).
(C) C5a-production is upregulated in the arthritic paw in DTHA compared to naı¨ve controls, measured by ELISA in whole-paw homogenate
supernatants. Mean shown, n¼ 5. ***: p 0.001, one-way ANOVA. (D) Median fluorescence intensity (MFI) of FITC conjugated to C5aR measured
by flow cytometry on neutrophils (PMN) and macrophages (Mj) in the lymph node draining the arthritic paw (dLN), in paw infiltrate and in blood,
measured 72 h after arthritis induction. Neutrophils were gated as CD45+CD19CD11b+Ly6G+, macrophages as CD45+CD19CD11b+Ly6GF4/80+
and monocytes in blood as CD45+CD19CD11b+Ly6GSSClowFSCint. Mean shown, n¼ 5–10. (E) Representative flow cytometry histograms showing
the mean fluorescence intensity (MFI) of FITC conjugated to either anti-C5aR or isotype control antibody. (F) Blood neutrophil count in DTHA
measured by flow cytometry. Dotted line represents blood neutrophil count in naı¨ve mice and grey shading 95% CI (mean: 251,968 cells/ml, 95% CI:
177,173–326,763 cells/ml). Mean ± 95% CI shown, n¼ 10. (G) Myeloperoxidase measured in whole-paw homogenate supernatants by ELISA.
Mean ± 95% CI shown, n¼ 10. Dotted line represents levels in naı¨ve mice and grey shading 95% CI (mean: 9.077 mg/g, 95% CI: 7.440–10.715mg/g,
n¼ 10).
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sought to investigate effects of the compound on the earliest
stages of arthritis development, as this would allow us to
more closely examine the early mechanistic effects of
C5aR-blockade on cell activation and migration. A single
dose of 500mg anti-C5aR given at arthritis induction led to a
reduced paw- and ankle swelling when measured over 60 h
(Figure 3A). Histopathological evaluation revealed that
synovitis, cartilage destruction and bone erosion were
attenuated, but also that extra-articular infiltration of inflam-
matory cells was not affected (Figure 3B–D). The overall
histopathology score was also reduced, as was the arthritis
score, which is defined as the sum of all the individual
evaluation parameters pertaining to an arthritic phenotype
(Figure 3C). Levels of the osteoclast-activating receptor-
activator of nuclear factor kB ligand (RANKL) were also
significantly reduced in the paws of anti-C5aR-treated mice
(Figure 3E), supporting the reduction in bone erosion
observed. In addition, levels of MPO were also reduced in
the paws of anti-C5aR-treated mice (Figure 3F), indicating
either reduced neutrophil recruitment, activation or both.
(A)
(B)
(C)
(D) (F) (G)
(E)
Figure 2. Treatment with anti-C5aR mAb ameliorates DTH arthritis. (A) Therapeutic treatment with 500 mg/mouse of anti-C5aR or isotype control Ab
(IgG2a.1) was started at time of challenge and continued until day 11 post arthritis induction where the study was terminated. (B) Treatment with anti-
C5aR ameliorated DTHA when begun at arthritis induction. Area under curve (AUC) values calculated from individual swelling curves over days 0–11.
Mean ± SEM shown, n¼ 10. *: p 0.05; **: p 0.01; ***: p 0.001, Student’s t-test. (C) Semi-quantitative histopathological scoring of arthritic and
inflammatory parameters in the two treatment groups at study termination on a scale of 0–3 (see ‘‘Materials and methods’’ section for details), n¼ 10.
*: p 0.05; **: p 0.01; ***: p 0.001, Student’s t-test with Welch’s correction. (D) Sum of the individual scores in C). Maximum possible score is
15. n¼ 10. ***: p 0.001, Student’s t-test with Welch’s correction. (E) Images show the metatarsal joint from the paw of a mouse from the
C5aR-treated group and a mouse from the IgG2a.1-treated control group with an arthritis sum score of 3.5 (mean: 2.8), and 8 (mean: 6.8), respectively,
at study termination on day 11. Arrows point towards areas of cartilage destruction in the images of Safranin O stains and towards TRAP-positive
osteoclasts in the images of TRAP stains. The stars indicate areas of extra-articular inflammation. BM: bone marrow; S: synovium. Magnification 10V,
scale bar represents 600 mm. (F) Levels of C5a protein in whole-paw homogenate supernatants in the two treatment groups measured by ELISA.
Mean ± SEM shown, n¼ 10. *: p 0.05; **: p 0.01, Student’s t-test. (G) Levels of the acute-phase protein serum amyloid P component (SAP) in
serum from the two treatment groups by ELISA. Mean ± SEM shown, n¼ 10. *: p 0.05, Student’s t-test.
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A reduction in circulating neutrophils and T cells was
observed in the anti-C5aR-treated group (Figure 3G) and
total leukocyte count was reduced in the popliteal lymph node
draining the arthritic paw (dPLN) in anti-C5aR-treated mice,
as was CD4+ T cell count (Figure 3H). Furthermore, a
tendency towards a reduction in neutrophil count in the dPLN
was also observed (Figure 3H). Together, these data demon-
strate that a single dose of anti-C5aR has the ability to
significantly reduce early onset disease development and
arthritic changes in DTHA by reducing numbers of CD4+ T
cells in the draining lymph node, reducing circulating
inflammatory cells and preventing arthritic changes in the
affected paw.
A single dose of anti-C5aR leads to reduced influx of
neutrophils into the joint space
Having demonstrated that a single dose of anti-C5aR could
reduce disease activity in the very early stages of DTHA, we
now investigated the effect of a single dose more closely on
infiltration of neutrophils and macrophages into the arthritic
(A) (B)
(D)
(G) (H)
(E)
(F)
(C)
Figure 3. Disease activity in DTHA is reduced 60 h following a single dose of anti-C5aR mAb. (A) Area under curve (AUC) of paw- and ankle
swelling, measured every day until 60 h after arthritis induction. Mean ± SEM shown, n¼ 10. *: p 0.05; **: p 0.01, Student’s t-test. (B) Semi-
quantitative histopathology scoring of arthritic and inflammatory parameters in the two treatment groups on a scale of 0–3 (see Material and methods
for details). n¼ 10. *: p 0.05; **: p 0.01; ***: p 0.001, Student’s t-test with Welch’s correction. (C) Sum of the individual scores in B (arthritis
sum score), and sum of the individual scores in B minus extra articular infiltration (arthritis score). Maximum possible score is 15 and 9, respectively.
n¼ 10. *: p 0.05; **: p 0.01, Student’s t-test with Welch’s correction. (D) Images show the metatarsal joint from the paw of a mouse from the
C5aR-treated group and a mouse from the IgG2a.1-treated control group with an arthritis sum score of 3 (mean: 5.6), and 6 (mean: 8.1), respectively, at
study termination at 60 h post arthritis induction. Arrows point towards areas of cartilage destruction in the images of Safranin O stains and towards
TRAP-positive osteoclasts in the images of TRAP stains. The stars indicate extra-articular inflammation. BM: bone marrow; S: synovium.
Magnification 10, scale bar represents 600 mm. (E) Levels of receptor-activator of nuclear factor kB ligand (RANKL) protein in whole-paw
homogenate supernatants from the two treatment groups measured by ELISA. Mean ± SEM shown, n¼ 10. **: p 0.01, Student’s t-test. (F) Levels of
myeloperoxidase (MPO) protein in whole-paw homogenate supernatants measured by ELISA. Mean ± SEM shown, n¼ 10, ***: p 0.001, Student’s
t-test. (G) Neutrophil and T cell counts in blood of mice treated with anti-C5aR or IgG2a.1. Neutrophils were defined as CD45+CD11b+Ly6G+ and T
cells as CD45+TCRb+. Mean ± SEM shown, n¼ 10. *: p 0.05, Student’s t-test. (H) Total leukocyte, neutrophil and CD4+ T cell count in the popliteal
lymph node draining the arthritic paw (dPLN) in mice treated with anti-C5aR or IgG2a.1. Neutrophils and T cells defined as above. Mean ± SEM
shown, n¼ 10. *: p 0.05, Student’s t-test.
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paw. Immunohistochemical stainings for macrophages and
neutrophils on whole-paw tissue sections from both treatment
groups were performed, and the numbers of these cells were
quantified using Visiomorph digitalised image analysis.
This method did not reveal a significant difference in total
neutrophil (Ly6B.2-positive) or macrophage (F4/80-positive)
infiltration into the arthritic paws (Figure 4A), despite there
being an effect of a single dose of anti-C5aR on clinical
disease parameters (Figure 3A). As automated digitalised
image analyses are not suitable for quantifying neutrophil and
macrophage infiltration specifically into the joint space and
surrounding synovium due to varying nature of synovial
tissue in arthritis, the Ly6B.2 and F4/80-stained sections were
scored by eye in a semi-quantitative manner instead (see
materials and methods for details of the scoring system). This
analysis revealed a significant difference in neutrophil
infiltration, with the anti-C5aR-treated animals displaying a
lower degree of infiltration into the joint space and synovium
compared to isotype control-treated mice (Figure 4C). No
difference could be detected when the same scoring system
was applied to F4/80-stained sections (Figure 4D). Together,
these data indicate that anti-C5aR does not have an effect on
neutrophil and macrophage recruitment to the total of the
affected paw after a single dose and they support the finding
that a single dose of anti-C5aR does not reduce total extra-
articular inflammation (Figure 3B). On the other hand, a
single dose of anti-C5aR reduced MPO protein levels in the
arthritic paw, which is an indirect way of estimating
neutrophil numbers in tissue, so a firm conclusion cannot
be made. Importantly, the present data does indicate that anti-
C5aR treatment has an effect on neutrophil spatial organisa-
tion locally in the inflamed synovium and in the joints.
A single dose of anti-C5aR leads to changes in
inflammatory biomarkers locally in the arthritic paw
To further investigate the pathways affected by blockade of
C5aR, and to investigate whether anti-C5aR leads to a
reduction in activation of inflammatory cells, arthritic paws
were harvested and homogenised 60 h post arthritis induction
and analysed for protein levels of a range of cytokines and
chemokines. The inflammatory cytokine IL-6 was signifi-
cantly decreased in the paws of anti-C5aR-treated mice and
there was a tendency towards a reduction in IL-17, while no
change in IL-1b or IL-10 was observed. Furthermore, the
chemoattractants CXCL1/KC, CXCL2/MIP-2, CXCL5/LIX
and lymphotactin were significantly reduced in the paws of
anti-C5aR-treated animals, as was G-CSF. Finally, vascular
endothelial growth factor (VEGF), basic fibroblast growth
factor (bFGF) and vascular cell VCAM-1 were also signifi-
cantly reduced in the paws of anti-C5aR-treated mice
(Table 1). These data demonstrate that a single dose of anti-
C5aR could rapidly mediate changes in local inflammatory
mediators, which are both markers of and important for the
activation and infiltration of a variety inflammatory cell
subsets, and for angiogenesis. Although a single dose of anti-
C5aR does not reduce neutrophil infiltration into the affected
paw at this time point, it could reduce the activation level of
the infiltrating neutrophils.
Discussion
The present study demonstrates the efficacy of a blocking,
non-cell-depleting anti-mouse C5aR mAb in the early stage of
arthritis development in the DTHA model, a single-paw
arthritis model with synchronised onset, low variation and
predictive validity for efficacy of anti-arthritic therapeutics
[24]. A multiple dose study showed reduction in paw swelling
and histopathological evaluation revealed reduced synovitis,
bone erosion, cartilage destruction, reduced new bone
formation and extra-articular inflammation. Importantly,
rapid onset effects of a single dose of anti-C5aR in DTHA
were apparent as little as 60 h after a single dose administered
at arthritis induction. Significant reduction in paw swelling,
synovitis, bone erosion, cartilage destruction and recruitment
of neutrophils to the joints and synovium was demonstrated.
The reduction in paw swelling observed was similar to the
reduction observed after treatment with etanercept or dexa-
methasone in a previous study in the DTHA model [24].
RANKL levels locally in the affected paw were also reduced,
indicating reduced osteoclast activation, which supports the
reduction in osteoclast activity observed in the histopatho-
logical evaluation. Numbers of neutrophils in circulation and
the draining popliteal lymph node were reduced following a
single dose of anti-C5aR, as was MPO and G-CSF protein
levels in the affected paw, indicating reduced neutrophil
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Figure 4. Anti-C5aR treatment reduces neutrophil infiltration into joints,
but not total quantity of neutrophils and macrophages in paws.
Digitalised image analysis (see ‘‘Materials and Methods’’ section for
details) of (A) neutrophils (Ly6B.2) and (B) macrophages (F4/80)
in DTHA paws at 60 h post arthritis induction after a single dose of
anti-C5aR or isotype control antibody. The results are given as tissue
area stained positive for F4/80 and Ly6B.2 of the entire paw area
(%). Mean shown, n¼ 9–10. Semi-quantitative visual scoring (see
Materials and Methods for details) of (C) neutrophil infiltration and
(D) macrophage infiltration into the joint space and synovium of DTHA
paws at 60 h post arthritis induction after a single dose of anti-C5aR or
isotype control antibody. Evaluation was performed on Ly6B.2-stained
(C) and F4/80 (D) sections. Range 0–3. Mean ± SEM shown, n¼ 9–10.
*: p 0.05, Student’s t-test with Welch’s correction.
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recruitment from the bone marrow. The reduction in paw
swelling could also be a result of impaired activation of
already infiltrating C5aR-positive cells, thus reducing overall
tissue inflammation. The first wave of neutrophils to reach the
paw after arthritis induction is most likely not fully dependent
on the C5a-C5aR axis, as it is also not in the delayed-type
hypersensitivity (DTH) and K/BxN models [29–32]. Indeed,
the initial extra-articular inflammation observed in DTHA is
likely to be a result of the DTH response in isolation and
unrelated to the anti-CII cocktail given, as a previous study
has shown that paw swelling 24 h after mBSA challenge was
comparable whether anti-CII had been given or not [24].
Complement activation and C5a production in DTHA most
likely takes place at the cartilage surfaces where the anti-CII
administered during induction localises and forms immune
complexes with cartilage CII. In the CAIA and CIA models
anti-CII antibodies deposit on cartilage surfaces and activate
complement [19,33], and in the K/BxN and K/BxN serum
transfer models glucose-6-phosphate isomerase (GPI)-anti-
GPI immune complexes deposit on the cartilage surfaces
and activate complement [34]. Cartilage surfaces are not very
rich in cells and thus lack the cell membrane-bound C3
inactivators decay-acceleration factor (DAF) and membrane
cofactor protein (MCP), so only soluble inhibitors and
surface sialic acid residues are present to dampen the
activation of complement pathways [34]. In addition, the
breakdown of cartilage that occurs during joint inflammation
can unmask molecules that can further contribute to the
activation of complement [33]. Together these circumstances
make the inflamed joint a location where the complement
equilibrium is unsteady and excessive activation is favoured,
which could be the reason for the pronounced effect of
blocking C5aR signalling at this site. In line with this, the
effect of anti-C5aR on neutrophil migration in the single-dose
study was isolated to the cells infiltrating the joints and
synovial tissue.
Levels of CXCL2/MIP-2 were lower in the paws of anti-
C5aR-treated mice at 60 h post arthritis induction in the
present study and this could indicate a lower level of
activation of the infiltrating neutrophils, as CXCL2/MIP-2
is secreted by activated neutrophils themselves [29] as well as
by macrophages and mast cells [35]. The chemoattractants
CXCL1/KC, CXCL5/LIX and lymphotactin, which were also
reduced in paws of anti-C5aR-treated mice 60 h after a single
dose, have been demonstrated to be upregulated in both RA
synovial tissue/fluid and other murine arthritis models
[36,37]. In addition, it is suggested that lymphotactin can
exert immunomodulatory effects through MMP release from
synovial fibroblasts and cytokine release from macrophages
in addition to its chemotactic properties [37]. The present data
indicate that C5aR signalling is important for the expression
of leukocyte chemoattractants in the earliest stages of arthritis
development and that a blockade of the receptor could
potentially represent a way of lowering leukocyte migration
and activation in the disease.
The observed reduction in G-CSF could be a contributing
factor to the more rapid resolution of inflammation observed in
DTHA after multiple doses of anti-C5aR, as fewer neutrophils
are thus released into circulation while neutrophils present in
the inflamed tissue undergo apoptosis. G-CSF is a major
cytokine for proliferation and survival of neutrophils and exerts
its effecs by down-regulating CXCL12 and CXCR4, which
leads to reduced neutrophil retention in the bone marrow [38].
C5a amplifies the production of G-CSF in vivo and in vitro, and
G-CSF in turn up-regulates C5aR on neutrophils [39]. G-CSF
can be produced by leukocytes, endothelial cells and fibro-
blasts, and the reduction observed in the present study could be
the direct result of blocking of C5aR on these cells.
IL-6 levels in paw tissue were also reduced after a single
dose of anti-C5aR. Neutrophils [40] and macrophages [41]
express IL-6 upon stimulation with C5a, and production of
this cytokine was attenuated when C5a was blocked by
Table 1. Reduction in protein biomarkers of inflammation in paw tissue following a single dose of anti-C5aR or IgG2a.1.
Analyte
Anti-C5aR-treated,
pg/g tissue (95% CI)
IgG2a.1-treated,
pg/g tissue (95% CI) % Reduction of meany p Value
Cytokines
IL-1b 950.2 (765.6–1135) 935 (774.6–1035) 1.6 0.89
IL-6 1097 (582.3–1612) 3873 (2235–5511) 71.7 0.0028
IL-10 4403 (3418–5388) 4280 (3320–5239) 2.9 0.84
IL-17 47.98 (30.28–65.67) 86.12 (43.34–128.9) 44.3 0.066
G-CSF 1681 (808.7–2562) 6129 (2584–9675) 72.6 0.013
GM-CSF 149.3 (57.3–241.4) 260 (174.5–345.5) 42.6 0.062
Chemokines
CXCL1/KC 6854 (3919–9788) 11630 (9374–13 886) 41.1 0.0092
CXCL2/MIP-2 7430 (4118–10742) 20677 (13320–28035) 64.1 0.0016
CXCL5/LIX 1134 (448.5–1819) 3301 (2227–4376) 65.6 0.0012
CXCL10/IP-10 4403 (3418–5388) 4280 (3320–5239) 2.9 0.84
CCL3/MIP-1a 3312 (2560–4065) 3361 (2522–4200) 1.5 0.92
CCL5/RANTES 1015 (863.1–1167) 1026 (835.1–1218) 1.1 0.91
Lymphotactin 2351 (2003–2699) 2836 (2416–3257) 17.1 0.030
Adhesion molecule
VCAM-1 439 (371–506.9) 503.4 (484–522) 12.8 0.027
Growth factors
VEGF 74.49 (55.89–93.09) 115.6 (89.77–141.5) 35.6 0.0091
bFGF 1567 (1048–2086) 2349 (1705–2993) 33.3 0.047
Whole-paw homogenates were analysed for protein levels of a range of inflammatory markers using multiplex analysis.
yAnti-C5aR-treated group compared to IgG2a-treated group 60 h after single-dose treatment, t-test, n¼ 10.
468 S. M. Atkinson et al. Autoimmunity, 2015; 48(7): 460–470
D
ow
nl
oa
de
d 
by
 [C
op
en
ha
ge
n U
niv
ers
ity
 L
ibr
ary
] a
t 0
0:0
7 3
1 M
arc
h 2
01
6 
antibodies or in C5aR/ mice [40]. The reduction in IL-6 in
paw tissue observed in the present study might therefore
reflect a direct effect of anti-C5aR on activation of neutro-
phils and macrophages in DTHA. IL-6 induces RANKL
expression by synovial fibroblasts and activates osteoclast
precursor cells and thus contributes to arthritis development
[42], and so the reduced IL-6 observed following anti-C5aR-
treatment could contribute to the reduction in bone erosion
observed. IL-17 is also a key mediator in inflammation-driven
bone erosion and is upstream from RANKL in arthritis [43].
The observed reduction in IL-17 following anti-C5aR treat-
ment in the present study indicates that reduction of Th17
effector T-cell activity is a mechanism of C5aR-blockade in
experimental arthritis. Vascular endothelial growth factor
(VEGF) and basic fibroblast growth factor (bFGF) were also
significantly reduced in paws of anti-C5aR-treated mice. Both
are implicated in RA pathology through their angiogenic and
proliferative effects in inflamed synovium [44–47]. The
infiltration and retention of inflammatory cells in RA
synovium is facilitated by upregulation of VCAM-1 on
endothelial cells and synovial fibroblasts in this tissue [48].
VCAM-1 was reduced in DTHA paws following anti-C5aR
treatment, and as C5aR is expressed on endothelial cells and
synovial fibroblasts [7] this reduction in VCAM-1 could
represent a direct effect of anti-C5aR treatment on these cells.
In support of this, it has been shown that C5aR/ mice have
lower expression of VCAM-1 mRNA than wild-type mice
after induction of CAIA [19].
Finally, we also observed an effect of C5aR-blockade on
the T cell compartment, which to our knowledge has not
previously been demonstrated in a murine arthritis model.
Numbers of total T cells in circulation was reduced, as was the
numbers of CD4+ T cells in the dPLN. Recent findings have
implicated C5a in the regulation of T-cell immunity [9,10,49],
but from our data it was not further possible to determine
whether the observed reductions in T cell subsets following
C5aR-blockade were a primary or secondary effect.
In summary, we demonstrate that treatment with anti-C5aR
mAb reduces disease activity in DTHA and prevents devel-
opment of severe arthritis. Importantly, rapid onset effects of
C5aR-blockade were apparent 60 h after a single dose. These
included a decrease in inflammatory cytokines and chemo-
attractants locally in the affected paws, indicating that anti-
C5aR-treatment could reduce inflammatory cell activation.
Reduction in the neutrophil marker MPO indicates impaired
neutrophil recruitment and activation. Immunohistochemistry
showed a reduced influx of neutrophils specifically into the
joint spaces and synovium, demonstrating that C5aR-signal-
ling is important for neutrophil recruitment into the inflamed
joints during the early stages of arthritis. Finally, an effect of
anti-C5aR on the T-cell compartment was also shown. In
conclusion, our study demonstrates that C5aR-blockade has
early-onset effects on recruitment, infiltration and activation
of inflammatory cells in experimental arthritis. Thus, data
from this preclinical study strengthen the potential of C5aR-
blockade as a treatment strategy for RA, and indicates that
blocking C5aR could be an option for treating flaring of the
disease, if treatment is initiated before full-blown joint
inflammation is present and perhaps prevent severe arthritis
from developing.
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